New hope for advanced colon cancer: AK112 combo enters phase 3 trial
NCT ID NCT06951503
First seen Mar 07, 2026 · Last updated Jun 09, 2026 · Updated 16 times
Summary
This phase 3 study compares a new drug, AK112, combined with chemotherapy against the standard treatment (bevacizumab plus chemo) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if the new combination helps patients live longer without their cancer growing. About 560 adults aged 18 to 75 with good performance status are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuanzhou, Guangdong, China
Contact
-
The Sixth Hospital,Sun Yat-sen University
RECRUITINGGuanzhou, Guangdong, 510000, China
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.